AU2013205445B2 - Antisense antiviral compound and method for treating picornavirus infection - Google Patents
Antisense antiviral compound and method for treating picornavirus infectionInfo
- Publication number
- AU2013205445B2 AU2013205445B2 AU2013205445A AU2013205445A AU2013205445B2 AU 2013205445 B2 AU2013205445 B2 AU 2013205445B2 AU 2013205445 A AU2013205445 A AU 2013205445A AU 2013205445 A AU2013205445 A AU 2013205445A AU 2013205445 B2 AU2013205445 B2 AU 2013205445B2
- Authority
- AU
- Australia
- Prior art keywords
- antisense antiviral
- viral
- antiviral compound
- subunits
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000000692 anti-sense effect Effects 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 208000005155 Picornaviridae Infections Diseases 0.000 title 1
- 241000709661 Enterovirus Species 0.000 abstract 1
- 206010014909 Enterovirus infection Diseases 0.000 abstract 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 241000709664 Picornaviridae Species 0.000 abstract 1
- 206010061494 Rhinovirus infection Diseases 0.000 abstract 1
- 108020000999 Viral RNA Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000017066 negative regulation of growth Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Abstract The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Picornaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Enterovirus and/or Rhinovirus infection in a mammal. The antisense antiviral compounds are substantially uncharged, including partially positively charged, morpholino oligonucleotides have a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with viral RNA sequences within a 32 nucleotide region of the viral 5' untranslated region identified by SEQ ID NO:4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013205445A AU2013205445B2 (en) | 2005-09-08 | 2013-04-26 | Antisense antiviral compound and method for treating picornavirus infection |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/715,888 | 2005-09-08 | ||
| US60/800,120 | 2006-05-11 | ||
| AU2006287530A AU2006287530A1 (en) | 2005-09-08 | 2006-09-08 | Antisense antiviral compound and method for treating picornavirus infection |
| AU2013205445A AU2013205445B2 (en) | 2005-09-08 | 2013-04-26 | Antisense antiviral compound and method for treating picornavirus infection |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006287530A Division AU2006287530A1 (en) | 2005-09-08 | 2006-09-08 | Antisense antiviral compound and method for treating picornavirus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013205445A1 AU2013205445A1 (en) | 2013-05-23 |
| AU2013205445B2 true AU2013205445B2 (en) | 2016-07-21 |
Family
ID=48444785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013205445A Expired - Fee Related AU2013205445B2 (en) | 2005-09-08 | 2013-04-26 | Antisense antiviral compound and method for treating picornavirus infection |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2013205445B2 (en) |
-
2013
- 2013-04-26 AU AU2013205445A patent/AU2013205445B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| WANG, A. et al., Antimicrobial Agents and Chemotherapy, 2001, Vol. 45, No. 4, pages 1043-1052 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013205445A1 (en) | 2013-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007030576A3 (en) | Antisense antiviral compound and method for treating picornavirus infection | |
| WO2007030691A3 (en) | Antisense antiviral compound and method for treating picornavirus infection | |
| WO2007103529A3 (en) | Antisense antiviral compound and method for treating arenavirus infection | |
| ATE491791T1 (en) | OLIGONUCLEOTIDE ANALOG AND METHOD FOR TREATING FLAVIVIRUS INFECTIONS | |
| WO2006033933A3 (en) | Antisense antiviral compound and method for treating ssrna viral infection | |
| WO2006047683A3 (en) | Antisense antiviral compound and method for treating influenza viral infection | |
| US11732262B2 (en) | Use of FUBP1 inhibitors for treating hepatitis B virus infection | |
| US20090176727A1 (en) | Double-stranded rna structures and constructs, and methods for generating and using the same | |
| CA2526893A1 (en) | Inhibition of the expression of huntingtin gene | |
| EP1507791A4 (en) | ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING MONOCATENARY RNA VIRAL INFECTION | |
| Israsena et al. | Inhibition of rabies virus replication by multiple artificial microRNAs | |
| EP1578933A4 (en) | COMPOSITIONS AND METHOD FOR INHIBITING ANGIOGENESIS BY RNA-IS | |
| NZ603603A (en) | Modulation of factor 11 expression | |
| AU2003284323A2 (en) | Double-stranded RNA structures and constructs, and methods for generating and using the same | |
| JP2013165733A (en) | Nucleic acid agent for downregulating h19, and method for using the same | |
| WO2005013905A3 (en) | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION | |
| EP2092078A4 (en) | Nuclease-resistant rna aptamer inhibiting replication of hepatitis c virus replicon | |
| WO2007044468A3 (en) | Method to treat flavivirus infection with sirna | |
| WO2005112636A3 (en) | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF PRIMATE POLYOMAVIRUS GENES | |
| MX2013003698A (en) | Prophylactic or therapeutic agent for fibrosis. | |
| AU2013205445B2 (en) | Antisense antiviral compound and method for treating picornavirus infection | |
| JP2008514202A (en) | Targeting reverse-strand intermediates of single-stranded viruses by RNAI | |
| Mohapatra et al. | Evaluation of in vitro inhibitory potential of small interfering RNAs directed against various regions of foot-and-mouth disease virus genome | |
| WO2009044294A3 (en) | Means and methods for the treatment of cataract and presbyopia | |
| WO2004071453A3 (en) | Compositions and methods for treatment of pouchitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |